Przejdź do zawartości

Kardiochirurgia i chirurgia naczyniowa (pediatria)

Optymalizacja i utrzymanie hemostazy

Środki antyfibrynolityczne

Avoiding transfusions in children undergoing cardiac surgery: a meta-analysis of randomized trials of aprotinin. (opens new window)

Arnold DM, Fergusson DA, Chan AK, Cook RJ, Fraser GA, Lim W, Blajchman MA, Cook DJ.

Źródło‎: Anesth Analg 2006;102(3):731-7.

Indeks‎: PubMed 16492820

DOI‎: 10.1213/01.ane.0000194954.64293.61

https://www.ncbi.nlm.nih.gov/pubmed/16492820 (opens new window)

A systematic review of the use of antifibrinolytic agents in pediatric surgery and implications for craniofacial use. (opens new window)

Basta MN, Stricker PA, Taylor JA.

Źródło‎: Pediatr Surg Int 2012;28(11):1059-69.

Indeks‎: PubMed 22940882

DOI‎: 10.1007/s00383-012-3167-6

https://www.ncbi.nlm.nih.gov/pubmed/22940882 (opens new window)

Aprotinin, transfusions, and kidney injury in neonates and infants undergoing cardiac surgery. (opens new window)

Bojan M, Vicca S, Boulat C, Gioanni S, Pouard P.

Źródło‎: Br J Anaesth 2012;108(5):830-7.

Indeks‎: PubMed 22362670

DOI‎: 10.1093/bja/aes002

https://www.ncbi.nlm.nih.gov/pubmed/22362670 (opens new window)

Comparison of epsilon aminocaproic acid and tranexamic acid in pediatric cardiac surgery. (opens new window)

Chauhan S, Das SN, Bisoi A, Kale S, Kiran U.

Źródło‎: J Cardiothorac Vasc Anesth 2004;18(2):141-3.

Indeks‎: PubMed 15073700

https://www.ncbi.nlm.nih.gov/pubmed/15073700 (opens new window)

Efficacy of aprotinin, epsilon aminocaproic acid, or combination in cyanotic heart disease. (opens new window)

Chauhan S, Kumar BA, Rao BH, Rao MS, Dubey B, Saxena N, Venugopal P.

Źródło‎: Ann Thorac Surg 2000;70(4):1308-12.

Indeks‎: PubMed 11081890

https://www.ncbi.nlm.nih.gov/pubmed/11081890 (opens new window)

The Bayer 022 compassionate-use pediatric study. (opens new window)

Coniff RF.

Źródło‎: Ann Thorac Surg 1998;65(6 Suppl):S31-3.

Indeks‎: PubMed 9647135

https://www.ncbi.nlm.nih.gov/pubmed/9647135 (opens new window)

Differential effects of aprotinin and tranexamic acid on outcomes and cytokine profiles in neonates undergoing cardiac surgery. (opens new window)

Graham EM, Atz AM, Gillis J, Desantis SM, Haney AL, Deardorff RL, Uber WE, Reeves ST, McGowan FX Jr, Bradley SM, Spinale FG.

Źródło‎: J Thorac Cardiovasc Surg 2012;143(5):1069-76.

Indeks‎: PubMed 22075061

DOI‎: 10.1016/j.jtcvs.2011.08.051

https://www.ncbi.nlm.nih.gov/pubmed/22075061 (opens new window)

Intraoperative tranexamic acid in pediatric bloodless cardiac surgery. (opens new window)

Hasegawa T, Oshima Y, Maruo A, Matsuhisa H, Tanaka A, Noda R, Yokoyama S, Iwasaki K.

Źródło‎: Asian Cardiovasc Thorac Ann 2014;22(9):1039-45.

Indeks‎: PubMed 24637029

DOI‎: 10.1177/0218492314527991

https://www.ncbi.nlm.nih.gov/pubmed/24637029 (opens new window)

The safety and efficacy of antifibrinolytic therapy in neonatal cardiac surgery. (opens new window)

Lin CY, Shuhaiber JH, Loyola H, Liu H, Del Nido P, DiNardo JA, Pigula FA.

Źródło‎: PLoS One 2015;10(5):e0126514.

Indeks‎: PubMed 25954976

DOI‎: 10.1371/journal.pone.0126514

https://www.ncbi.nlm.nih.gov/pubmed/25954976 (opens new window)

Tranexamic acid versus ɛ-aminocaproic acid: efficacy and safety in paediatric cardiac surgery. (opens new window)

Martin K, Breuer T, Gertler R, Hapfelmeier A, Schreiber C, Lange R, Hess J, Wiesner G.

Źródło‎: Eur J Cardiothorac Surg 2011;39(6):892-7.

Indeks‎: PubMed 21115357

DOI‎: 10.1016/j.ejcts.2010.09.041

https://www.ncbi.nlm.nih.gov/pubmed/21115357 (opens new window)

Replacement of aprotinin by ε-aminocaproic acid in infants undergoing cardiac surgery: consequences for blood loss and outcome. (opens new window)

Martin K, Gertler R, MacGuill M, Mayr NP, Hapfelmeier A, Hörer J, Vogt M, Tassani P, Wiesner G.

Źródło‎: Br J Anaesth 2013;110(4):615-21.

Indeks‎: PubMed 23213034

DOI‎: 10.1093/bja/aes430

https://www.ncbi.nlm.nih.gov/pubmed/23213034 (opens new window)

Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. (opens new window)

Miller BE, Tosone SR, Tam VK, Kanter KR, Guzzetta NA, Bailey JM, Levy JH.

Źródło‎: Ann Thorac Surg 1998;66(2):535-40; discussion 541.

Indeks‎: PubMed 9725399

https://www.ncbi.nlm.nih.gov/pubmed/9725399 (opens new window)

Efficacy of tranexamic acid as compared to aprotinin in open heart surgery in children. (opens new window)

Muthialu N, Balakrishnan S, Sundar R, Muralidharan S.

Źródło‎: Ann Card Anaesth 2015;18(1):23-6.

Indeks‎: PubMed 25566706

DOI‎: 10.4103/0971-9784.148316

https://www.ncbi.nlm.nih.gov/pubmed/25566706 (opens new window)

Comparative analysis of antifibrinolytic medications in pediatric heart surgery. (opens new window)

Pasquali SK, Li JS, He X, Jacobs ML, O'Brien SM, Hall M, Jaquiss RD, Welke KF, Peterson ED, Shah SS, Jacobs JP.

Źródło‎: J Thorac Cardiovasc Surg 2012;143(3):550-7.

Indeks‎: PubMed 22264414

DOI‎: 10.1016/j.jtcvs.2011.06.048

https://www.ncbi.nlm.nih.gov/pubmed/22264414 (opens new window)

Effective tranexamic acid concentration for 95% inhibition of tissue-type plasminogen activator induced hyperfibrinolysis in children with congenital heart disease: A prospective, controlled, in-vitro study. (opens new window)

Rozen L, Faraoni D, Sanchez Torres C, Willems A, Noubouossie DC, Barglazan D, Van der Linden P, Demulder A.

Źródło‎: Eur J Anaesthesiol 2015;32(12):844-50.

Indeks‎: PubMed 26258658

DOI‎: 10.1097/EJA.0000000000000316

https://www.ncbi.nlm.nih.gov/pubmed/26258658 (opens new window)

Comparison of different doses of ε-aminocaproic acid in children for tetralogy of Fallot surgery: clinical efficacy and safety. (opens new window)

Sarupria A, Makhija N, Lakshmy R, Kiran U.

Źródło‎: J Cardiothorac Vasc Anesth 2013;27(1):23-9.

Indeks‎: PubMed 22995453

DOI‎: 10.1053/j.jvca.2012.07.001

https://www.ncbi.nlm.nih.gov/pubmed/22995453 (opens new window)

Comparison of three dose regimens of aprotinin in infants undergoing the arterial switch operation. (opens new window)

Verma YS, Chauhan S, Bisoi AK, Gharde P, Kiran U, Das SN.

Źródło‎: Ann Card Anaesth 2010;13(2):110-5.

Indeks‎: PubMed 20442540

DOI‎: 10.4103/0971-9784.62935

https://www.ncbi.nlm.nih.gov/pubmed/20442540 (opens new window)

Pharmacokinetics of tranexamic acid in neonates, infants, and children undergoing cardiac surgery with cardiopulmonary bypass. (opens new window)

Wesley MC, Pereira LM, Scharp LA, Emani SM, McGowan FX Jr, DiNardo JA.

Źródło‎: Anesthesiology 2015;122(4):746-58.

Indeks‎: PubMed 25585004

DOI‎: 10.1097/ALN.0000000000000570

https://www.ncbi.nlm.nih.gov/pubmed/25585004 (opens new window)

Efficacy and safety of aprotinin in neonatal congenital heart operations. (opens new window)

Wilder NS, Kavarana MN, Voepel-Lewis T, Paugh T, Lee T, Ohye RG.

Źródło‎: Ann Thorac Surg 2011;92(3):958-63.

Indeks‎: PubMed 21871283

DOI‎: 10.1016/j.athoracsur.2011.04.094

https://www.ncbi.nlm.nih.gov/pubmed/21871283 (opens new window)

The effect of preoperative tranexamic acid on blood loss after cardiac operations in children. (opens new window)

Zonis Z, Seear M, Reichert C, Sett S, Allen C.

Źródło‎: J Thorac Cardiovasc Surg 1996;111(5):982-7.

Indeks‎: PubMed 8622323

https://www.ncbi.nlm.nih.gov/pubmed/8622323 (opens new window)

Rekombinowany aktywowany czynnik VII (rFVIIa)

Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. (opens new window)

Agarwal HS, Bennett JE, Churchwell KB, Christian KG, Drinkwater DC Jr, He Y, Taylor MB.

Źródło‎: Ann Thorac Surg 2007;84(1):161-8.

Indeks‎: PubMed 17588404

DOI‎: 10.1016/j.athoracsur.2007.02.051

https://www.ncbi.nlm.nih.gov/pubmed/17588404 (opens new window)

Pediatric off-label use of recombinant factor VIIa. (opens new window)

Alten JA, Benner K, Green K, Toole B, Tofil NM, Winkler MK.

Źródło‎: Pediatrics 2009;123(3):1066-72.

Indeks‎: PubMed 19255041

DOI‎: 10.1542/peds.2008-1685

https://www.ncbi.nlm.nih.gov/pubmed/19255041 (opens new window)

Factor VII for excessive bleeding following congenital heart disease surgery. (opens new window)

Changlani DK, Devendaran V, Murmu UC, Ganesan S, Varghese R, Kumar RS.

Źródło‎: Asian Cardiovasc Thorac Ann 2012;20(2):120-5.

Indeks‎: PubMed 22499956

DOI‎: 10.1177/0218492311433614

https://www.ncbi.nlm.nih.gov/pubmed/22499956 (opens new window)

Use of recombinant factor VIIa for uncontrolled bleeding in neonates after cardiopulmonary bypass. (opens new window)

Guzzetta NA, Huch S, Fernandez JD, Tosone SR, Miller BE.

Źródło‎: Paediatr Anaesth 2009;19(4):364-70.

Indeks‎: PubMed 19143947

DOI‎: 10.1111/j.1460-9592.2008.02905.x

https://www.ncbi.nlm.nih.gov/pubmed/19143947 (opens new window)

Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients. (opens new window)

Guzzetta NA, Russell IA, Williams GD.

Źródło‎: Anesth Analg 2012;115(2):364-78.

Indeks‎: PubMed 22652310

DOI‎: 10.1213/ANE.0b013e31825aff10

https://www.ncbi.nlm.nih.gov/pubmed/22652310 (opens new window)

Is recombinant activated factor VII effective in the treatment of excessive bleeding after paediatric cardiac surgery? (opens new window)

Okonta KE, Edwin F, Falase B.

Źródło‎: Interact Cardiovasc Thorac Surg 2012;15(4):690-4.

Indeks‎: PubMed 22811512

DOI‎: 10.1093/icvts/ivs309

https://www.ncbi.nlm.nih.gov/pubmed/22811512 (opens new window)

Cardiac surgery without blood products in a Jehovah's Witness child with factor VII deficiency. (opens new window)

Pérez-Ferrer A, Gredilla E, de Vicente J, Laporta Y.

Źródło‎: J Cardiothorac Vasc Anesth 2012;26(4):651-3.

Indeks‎: PubMed 21924639

DOI‎: 10.1053/j.jvca.2011.07.012

https://www.ncbi.nlm.nih.gov/pubmed/21924639 (opens new window)

Use of recombinant activated factor VII for controlling refractory postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. (opens new window)

Pychyńska-Pokorska M, Pągowska-Klimek I, Krajewski W, Moll JJ.

Źródło‎: J Cardiothorac Vasc Anesth 2011;25(6):987-94.

Indeks‎: PubMed 21835642

DOI‎: 10.1053/j.jvca.2011.05.012

https://www.ncbi.nlm.nih.gov/pubmed/21835642 (opens new window)

Increased recombinant activated factor VII use and need for surgical reexploration following a switch from aprotinin to epsilon-aminocaproic acid in infant cardiac surgery. (opens new window)

Scott JP, Costigan DJ, Hoffman GM, Simpson PM, Dasgupta M, Punzalan R, Berens RJ, Tweddell JS, Stuth EA.

Źródło‎: J Clin Anesth 2014;26(3):204-11.

Indeks‎: PubMed 24809789

DOI‎: 10.1016/j.jclinane.2013.10.015

https://www.ncbi.nlm.nih.gov/pubmed/24809789 (opens new window)

Recombinant activated factor VII for hemorrhage after pediatric cardiac surgery. (opens new window)

Singh SP, Chauhan S, Choudhary M, Vasdev S, Talwar S.

Źródło‎: Asian Cardiovasc Thorac Ann 2012;20(1):19-23.

Indeks‎: PubMed 22371937

DOI‎: 10.1177/0218492311432584

https://www.ncbi.nlm.nih.gov/pubmed/22371937 (opens new window)

Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant. (opens new window)

Tobias JD, Berkenbosch JW, Russo P.

Źródło‎: Pediatr Crit Care Med 2003;4(1):49-51.

Indeks‎: PubMed 12656542

DOI‎: 10.1097/01.PCC.0000031472.55687.4E

https://www.ncbi.nlm.nih.gov/pubmed/12656542 (opens new window)

Recombinant factor VIIa to control excessive bleeding following surgery for congenital heart disease in pediatric patients. (opens new window)

Tobias JD, Simsic JM, Weinstein S, Schechter W, Kartha V, Michler R.

Źródło‎: J Intensive Care Med 2004;19(5):270-3.

Indeks‎: PubMed 15358945

DOI‎: 10.1177/0885066604267783

https://www.ncbi.nlm.nih.gov/pubmed/15358945 (opens new window)

Recombinant activated factor VII in cardiac surgery: a systematic review. (opens new window)

Warren O, Mandal K, Hadjianastassiou V, Knowlton L, Panesar S, John K, Darzi A, Athanasiou T.

Źródło‎: Ann Thorac Surg 2007;83(2):707-14.

Indeks‎: PubMed 17258029

DOI‎: 10.1016/j.athoracsur.2006.10.033

https://www.ncbi.nlm.nih.gov/pubmed/17258029 (opens new window)

Defining the role of recombinant activated factor VII in pediatric cardiac surgery: where should we go from here? (opens new window)

Warren OJ, Rogers PL, Watret AL, de Wit KL, Darzi AW, Gill R, Athanasiou T.

Źródło‎: Pediatr Crit Care Med 2009;10(5):572-82.

Indeks‎: PubMed 19451849

DOI‎: 10.1097/PCC.0b013e3181a642d5

https://www.ncbi.nlm.nih.gov/pubmed/19451849 (opens new window)

Decreasing the need for transfusion: infant cardiac surgery using hemodilution and recombinant factor VIIa. (opens new window)

Winch PD, Naguib AN, Bradshaw JR, Galantowicz M, Tobias JD.

Źródło‎: Pediatr Cardiol 2013;34(1):119-24.

Indeks‎: PubMed 22760694

DOI‎: 10.1007/s00246-012-0398-1

https://www.ncbi.nlm.nih.gov/pubmed/22760694 (opens new window)

Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder. (opens new window)

Yilmaz D, Karapinar B, Balkan C, Akisü M, Kavakli K.

Źródło‎: Pediatr Hematol Oncol 2008;25(4):301-11.

Indeks‎: PubMed 18484474

DOI‎: 10.1080/08880010802016904

https://www.ncbi.nlm.nih.gov/pubmed/18484474 (opens new window)

Koncentraty czynników krzepnięcia

Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. (opens new window)

Cui Y, Hei F, Long C, Feng Z, Zhao J, Yan F, Wang Y, Liu J.

Źródło‎: Artif Organs 2010;34(11):955-60.

Indeks‎: PubMed 21092037

DOI‎: 10.1111/j.1525-1594.2010.01148.x

https://www.ncbi.nlm.nih.gov/pubmed/21092037 (opens new window)

Plasma fibrinogen concentration is correlated with postoperative blood loss in children undergoing cardiac surgery. A retrospective review. (opens new window)

Faraoni D, Willems A, Savan V, Demanet H, De Ville A, Van der Linden P.

Źródło‎: Eur J Anaesthesiol 2014;31(6):317-26.

Indeks‎: PubMed 24503704

DOI‎: 10.1097/EJA.0000000000000043

https://www.ncbi.nlm.nih.gov/pubmed/24503704 (opens new window)

Efficacy and safety of fibrinogen concentrate in surgical patients: a meta-analysis of randomized controlled trials. (opens new window)

Fominskiy E, Nepomniashchikh VA, Lomivorotov VV, Monaco F, Vitiello C, Zangrillo A, Landoni G.

Źródło‎: J Cardiothorac Vasc Anesth 2016;30(5):1196-204.

Indeks‎: PubMed 27493092

DOI‎: 10.1053/j.jvca.2016.04.015

https://www.ncbi.nlm.nih.gov/pubmed/27493092 (opens new window)

Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: a randomized pilot trial. (opens new window)

Galas FR, de Almeida JP, Fukushima JT, Vincent JL, Osawa EA, Zeferino S, Câmara L, Guimarães VA, Jatene MB, Hajjar LA.

Źródło‎: J Thorac Cardiovasc Surg 2014;148(4):1647-55.

Indeks‎: PubMed 24951020

DOI‎: 10.1016/j.jtcvs.2014.04.029

https://www.ncbi.nlm.nih.gov/pubmed/24951020 (opens new window)

Four-factor prothrombin complex concentrates in paediatric patients—a retrospective case series. (opens new window)

Noga T, Bruce AA, Blain H, Nahirniak S.

Źródło‎: Vox Sang 2016;110(3):253-7.

Indeks‎: PubMed 26509839

DOI‎: 10.1111/vox.12353

https://www.ncbi.nlm.nih.gov/pubmed/26509839 (opens new window)

Środki hemostatyczne o działaniu miejscowym

A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. (opens new window)

Achneck HE, Sileshi B, Jamiolkowski RM, Albala DM, Shapiro ML, Lawson JH.

Źródło‎: Ann Surg 2010;251(2):217-28.

Indeks‎: PubMed 20010084

DOI‎: 10.1097/SLA.0b013e3181c3bcca

https://www.ncbi.nlm.nih.gov/pubmed/20010084 (opens new window)

Resternotomy in pediatric cardiac surgery: CoSeal initial experience. (opens new window)

Pace Napoleone C, Oppido G, Angeli E, Gargiulo G.

Źródło‎: Interact Cardiovasc Thorac Surg 2007;6(1):21-3.

Indeks‎: PubMed 17669759

DOI‎: 10.1510/icvts.2006.141531

https://www.ncbi.nlm.nih.gov/pubmed/17669759 (opens new window)

Badania różnicujące krwawienie chirurgiczne z krwawieniem z koagulopatii (TEG)

Utility of Sonoclot analysis and tranexamic acid in tetralogy of Fallot patients undergoing intracardiac repair. (opens new window)

Aggarwal V, Kapoor PM, Choudhury M, Kiran U, Chowdhury U.

Źródło‎: Ann Card Anaesth 2012;15(1):26-31.

Indeks‎: PubMed 22234018

DOI‎: 10.4103/0971-9784.91477

https://www.ncbi.nlm.nih.gov/pubmed/22234018 (opens new window)

Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. (opens new window)

Cui Y, Hei F, Long C, Feng Z, Zhao J, Yan F, Wang Y, Liu J.

Źródło‎: Artif Organs 2010;34(11):955-60.

Indeks‎: PubMed 21092037

DOI‎: 10.1111/j.1525-1594.2010.01148.x

https://www.ncbi.nlm.nih.gov/pubmed/21092037 (opens new window)

Thromboelastometry-guided intraoperative haemostatic management reduces bleeding and red cell transfusion after paediatric cardiac surgery. (opens new window)

Nakayama Y, Nakajima Y, Tanaka KA, Sessler DI, Maeda S, Iida J, Ogawa S, Mizobe T.

Źródło‎: Br J Anaesth 2015;114(1):91-102.

Indeks‎: PubMed 25303988

DOI‎: 10.1093/bja/aeu339

https://www.ncbi.nlm.nih.gov/pubmed/25303988 (opens new window)

KARDIOCHIRURGIA I CHIRURGIA NACZYNIOWA (PEDIATRIA)
Optymalizacja i utrzymanie hemostazy
polski
Optymalizacja i utrzymanie hemostazy
https://assetsnffrgf-a.akamaihd.net/assets/ct/1add6d1d93/images/syn_placeholder_sqr.png

Komitet Łączności ze Szpitalami (KŁS)

Bezpłatna, ogólnoświatowa pomoc dostępna 24 godziny na dobę dla lekarzy opiekujących się Świadkami Jehowy.

Kontakt

Informacje medyczne — pakiety

Uwzględnione tematy: Kliniczne strategie postępowania bez transfuzji w krwotoku i niedokrwistości, religijne i etyczne stanowisko Świadków Jehowy w sprawie leczenia oraz usługi świadczone środowisku medycznemu przy pomocy ogólnoświatowej sieci Komitetów Łączności ze Szpitalami.

Materiały do pobrania

Materiały wideo

Możliwości leczenia oraz czynniki medyczne i etyczne dla lekarzy, którzy leczą Świadków Jehowy.

Zobacz